Immunoprecise Antibodies Ltd Stock Toronto S.E.
Equities
TQY
CA87588T2020
Pharmaceuticals
Sales 2024 * | 24.59M 18.05M | Sales 2025 * | 29.82M 21.88M | Capitalization | 39.9M 29.29M |
---|---|---|---|---|---|
Net income 2024 * | -12M -8.81M | Net income 2025 * | -9M -6.61M | EV / Sales 2024 * | 1.62 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.34 x |
P/E ratio 2024 * |
-3.16
x | P/E ratio 2025 * |
-4.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.41% |
Latest transcript on Immunoprecise Antibodies Ltd
Managers | Title | Age | Since |
---|---|---|---|
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
Kristin Taylor
DFI | Director of Finance/CFO | - | 23-09-28 |
Ilse Roodink
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mitchell Levine
CHM | Chairman | - | - |
Chris Buyse
BRD | Director/Board Member | 59 | 23-09-04 |
Jennifer Bath
CEO | Chief Executive Officer | - | 18-02-20 |
1st Jan change | Capi. | |
---|---|---|
-1.64% | 90.28B | |
-0.66% | 39.5B | |
-15.83% | 31.71B | |
+61.79% | 26.41B | |
-21.68% | 14.34B | |
-8.73% | 12.89B | |
-10.32% | 11.8B | |
-45.77% | 10.95B | |
+3.30% | 8.85B |